Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161


Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.

Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR.

J Thorac Oncol. 2013 Jan;8(1):19-30. doi: 10.1097/JTO.0b013e31827628ff.


Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.

Christoph DC, Reyna-Asuncion B, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Gauler TC, Wohlschlaeger J, Schuler M, Eberhardt WE, Hirsch FR.

Clin Lung Cancer. 2014 Sep;15(5):320-30.e1-3. doi: 10.1016/j.cllc.2014.05.002. Epub 2014 Jun 3.


Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.

Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM.

J Thorac Oncol. 2013 Jul;8(7):930-9. doi: 10.1097/JTO.0b013e318292c500.


Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ, Yang PC.

Lung Cancer. 2011 Oct;74(1):132-8. doi: 10.1016/j.lungcan.2011.01.024. Epub 2011 Mar 1.


Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.

Igawa S, Ryuge S, Wada M, Otani S, Maki S, Takakura A, Katono K, Sasaki J, Sato Y, Masuda N.

Chemotherapy. 2012;58(4):313-20. doi: 10.1159/000343048. Epub 2012 Nov 7.


Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.

Fennell DA, Myrand SP, Nguyen TS, Ferry D, Kerr KM, Maxwell P, Moore SD, Visseren-Grul C, Das M, Nicolson MC.

PLoS One. 2014 Sep 24;9(9):e107455. doi: 10.1371/journal.pone.0107455. eCollection 2014.


Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.

Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1125-32. doi: 10.1007/s00280-013-2299-2. Epub 2013 Sep 26. Review.


Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC).

Alvarez-Fernandez C, Perez-Arnillas Q, Ruiz-Echeverria L, Rodriguez-Rubi D, Sanchez-Lorenzo L, Li-Torres W, Izquierdo-Manuel M, Berros JP, Luque-Cabal M, Jimenez-Fonseca P, Villanueva-Palicio N, Esteban-Gonzalez E.

Invest New Drugs. 2014 Apr;32(2):377-81. doi: 10.1007/s10637-013-9992-1. Epub 2013 Aug 4.


Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.

Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A.

Lung Cancer. 2012 Oct;78(1):92-9. doi: 10.1016/j.lungcan.2012.07.009. Epub 2012 Aug 11.


Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.

Hou J, Lambers M, den Hamer B, den Bakker MA, Hoogsteden HC, Grosveld F, Hegmans J, Aerts J, Philipsen S.

J Thorac Oncol. 2012 Jan;7(1):105-14. doi: 10.1097/JTO.0b013e3182352a45.


Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.

Sun JM, Ahn JS, Jung SH, Sun J, Ha SY, Han J, Park K, Ahn MJ.

J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29.


The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy.

Yang M, Fan WF, Pu XL, Meng LJ, Wang J.

J Chemother. 2017 Apr;29(2):106-112. doi: 10.1080/1120009X.2016.1254940. Epub 2016 Nov 21.


Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.

Sun Y, Wu YL, Zhou CC, Zhang L, Zhang L, Liu XY, Yu SY, Jiang GL, Li K, Qin SK, Ma SL, Han L, Quinlivan M, Orlando M, Zhang XQ.

Lung Cancer. 2013 Feb;79(2):143-50. doi: 10.1016/j.lungcan.2012.10.015. Epub 2012 Nov 20.


Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.

Lee SH, Noh KB, Lee JS, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kim CH, Kang KH, In KH.

Lung Cancer. 2013 Jul;81(1):102-8. doi: 10.1016/j.lungcan.2013.03.002. Epub 2013 Mar 22.


Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.

Ceppi P, Rapa I, Lo Iacono M, Righi L, Giorcelli J, Pautasso M, Billè A, Ardissone F, Papotti M, Scagliotti GV.

Int J Cancer. 2012 Apr 15;130(8):1777-86. doi: 10.1002/ijc.26188. Epub 2011 Aug 5.


Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.

Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Cuello M, Corrales L, Martín C, Ortiz C, Franco S, Rosell R; CLICaP.

PLoS One. 2016 May 18;11(5):e0154293. doi: 10.1371/journal.pone.0154293. eCollection 2016.

Supplemental Content

Support Center